Cardarine reddit

The Reddit discourse on Cardarine spans years of anecdotal logs, dosing debates, and warnings about cancer risk — but almost none of it engages with the core reason the compound exists: to activate PPARδ, a nuclear receptor that rewires skeletal muscle metabolism toward fat oxidation. That shift explains both the endurance effects and the tumor promotion signal that ended clinical development.

A PPARδ Agonist Developed for Metabolic Disease, Not a SARM

GW-501516, marketed under the research name Cardarine and sometimes called GW1516, is a synthetic small-molecule agonist of peroxisome proliferator-activated receptor delta (PPARδ, also designated PPARβ/δ in some literature). It is not a selective androgen receptor modulator. It does not bind the androgen receptor. The chemical structure is C₂₁H₁₈F₃NO₃S₂ with a molecular weight of 453.49 Da.

GlaxoSmithKline and Ligand Pharmaceuticals co-developed GW-501516 in the 1990s as part of a drug discovery program targeting dyslipidemia and metabolic syndrome. The compound was designed to modulate how skeletal muscle, heart tissue, and adipocytes handle lipids and produce energy. Early preclinical work showed that activating PPARδ in mice shifted substrate preference away from glucose and toward fatty acid oxidation, which raised interest in potential applications for type 2 diabetes, obesity, and cardiovascular risk reduction. The compound advanced through Phase I and Phase II clinical trials but was discontinued in 2007 when two-year rodent studies revealed a dose-dependent increase in tumor formation across multiple organs.

Despite its origin in pharmaceutical R&D, Cardarine found its way into fitness and bodybuilding communities where it is often incorrectly grouped with SARMs due to overlapping distribution channels and similar use cases. The receptor it targets — PPARδ — has nothing to do with androgenic signaling.

How PPARδ Activation Reprograms Muscle Metabolism

PPARδ is a ligand-activated transcription factor that sits in the nucleus of cells, waiting for a chemical signal. When GW-501516 binds to PPARδ, the receptor changes shape, recruits coactivator proteins, and then binds to specific DNA sequences called peroxisome proliferator response elements (PPREs) in the promoter regions of target genes.

This binding event turns on gene expression programs that increase fatty acid uptake and oxidation. Skeletal muscle fibers exposed to GW-501516 upregulate enzymes involved in mitochondrial beta-oxidation — the process of breaking down long-chain fatty acids for ATP production. Proteins such as carnitine palmitoyltransferase 1 (CPT1), medium-chain acyl-CoA dehydrogenase (MCAD), and uncoupling protein 3 (UCP3) all see increased expression. The net effect is that treated muscle cells burn more fat and produce less lactate during sustained contraction.

PPARδ is expressed most abundantly in tissues with high oxidative capacity: type I (slow-twitch) muscle fibers, cardiac myocytes, brown adipose tissue, and the brain. In rodent models, chronic GW-501516 administration shifts muscle fiber type composition toward oxidative phenotypes and increases mitochondrial density. These changes are mechanistically distinct from the satellite cell activation or protein synthesis signaling seen with anabolic compounds.

GW-501516 also suppresses nuclear factor-kappa B (NF-κB) signaling in some cell types, which may explain anti-inflammatory effects observed in preclinical atherosclerosis models. In macrophages, PPARδ activation reduces the expression of pro-inflammatory cytokines such as TNF-α and IL-1β. In endothelial cells, it improves nitric oxide bioavailability and reduces oxidative stress markers. These effects are secondary to the metabolic reprogramming in skeletal muscle but generated interest in vascular biology applications.

Rodent Data Shows Endurance Gains and Tumor Acceleration

The most cited study is a 2008 paper from Ron Evans' group at the Salk Institute, published in Cell. Sedentary mice treated with GW-501516 for four weeks showed a 68% increase in running time to exhaustion compared to vehicle-treated controls. Skeletal muscle from treated animals had increased expression of oxidative metabolism genes, higher mitochondrial content, and reduced lactate accumulation during forced exercise. The compound did not change body weight or muscle mass but altered substrate utilization.

A follow-up experiment in the same paper combined GW-501516 with endurance training. Trained mice given the compound ran 70% longer than trained mice given vehicle, and muscle biopsies showed synergistic increases in slow-twitch fiber markers. This dataset is frequently cited in anecdotal logs as the "mouse study" that justifies Cardarine's reputation as an endurance enhancer. The study used doses equivalent to ~10 mg/kg in mice, though cross-species dose extrapolation is imprecise.

In lipid metabolism studies, GW-501516 improved high-density lipoprotein (HDL) cholesterol and reduced triglycerides in obese rhesus monkeys. A Phase II clinical trial in humans with dyslipidemia showed a 10-20% increase in HDL after 12 weeks of treatment at 2.5–10 mg/day. Low-density lipoprotein (LDL) and apolipoprotein B also trended downward. These trials were halted in 2007 before efficacy endpoints could be fully assessed.

The reason for discontinuation was consistent across two independent two-year carcinogenicity studies in rats and mice. Animals dosed with GW-501516 developed significantly higher rates of tumors in the liver, bladder, stomach, tongue, skin, and testes compared to controls. Tumor incidence increased with dose and duration of exposure. Importantly, this was not a single aberrant finding — it replicated across strains, species, and multiple organ systems. The mechanism is suspected to involve sustained mitogenic signaling through PPARδ in rapidly dividing epithelial cells, though the exact pathway is not fully characterized.

No long-term human safety data exists because all human trials were terminated before chronic exposure could be evaluated. The longest human exposure in published studies was 12 weeks. For research purposes only, the compound remains available through gray-market suppliers, but no regulatory body has approved it for any indication.

Dose, Half-Life, and Practical Research Parameters

Published rodent studies typically used doses of 5–10 mg/kg/day, administered orally. In human Phase II trials, doses ranged from 2.5 mg to 10 mg per day. Anecdotal reports on forums such as Reddit frequently describe self-administered doses of 10–20 mg/day, though these figures are not derived from controlled research and lack any pharmacokinetic validation.

The half-life of GW-501516 in humans is approximately 16–24 hours based on Phase I pharmacokinetic data. This allows once-daily dosing. Oral bioavailability is high in rodents, and no significant first-pass metabolism issues were reported in clinical trials. The compound is metabolized primarily by hepatic enzymes, though specific CYP isoforms have not been extensively mapped in the public literature.

PPARδ agonism does not suppress endogenous testosterone production or affect luteinizing hormone or follicle-stimulating hormone, which distinguishes it mechanistically from androgens and SARMs. No post-cycle therapy is required from an endocrine standpoint. However, lipid changes and potential effects on hepatic function make baseline and follow-up bloodwork advisable in any research protocol involving this compound.

Storage recommendations are not formally published, but peptide and small-molecule research standards suggest storage at -20°C for long-term stability, protected from light. Once reconstituted (if applicable) or opened, stability data is limited.

Drug interaction studies are minimal. PPARδ activation can theoretically interact with other lipid-modulating agents or mitochondrial electron transport chain inhibitors, but no formal contraindication list exists.

FAQ

Q: Is Cardarine actually a SARM?

No. GW-501516 does not bind the androgen receptor and does not function as a selective androgen receptor modulator. It is a PPARδ agonist, which means it works through a completely different receptor and signaling pathway. The confusion stems from its distribution alongside compounds like Ostarine and RAD-140 in research chemical markets, not from its pharmacology.

Q: Why was Cardarine pulled from clinical trials?

Two-year carcinogenicity studies in rats and mice showed dose-dependent increases in tumor formation across multiple organ systems, including the liver, bladder, stomach, and testes. The signal was consistent and reproducible, not an isolated finding. GlaxoSmithKline terminated all human trials in 2007 due to this cancer risk, and no long-term human safety data exists.

Q: What is the typical dose range reported in research contexts?

Rodent studies used 5–10 mg/kg/day. Human Phase II trials tested 2.5–10 mg/day. Anecdotal self-administration reports, particularly on Reddit and bodybuilding forums, describe 10–20 mg/day, but these are not validated by pharmacokinetic studies and carry unknown safety profiles given the absence of chronic human exposure data.

Q: Does Cardarine affect testosterone levels?

No. PPARδ agonism does not suppress the hypothalamic-pituitary-gonadal axis. Unlike anabolic steroids or SARMs, GW-501516 does not reduce endogenous testosterone, luteinizing hormone, or follicle-stimulating hormone. It does not require post-cycle endocrine recovery protocols.

Q: How long does GW-501516 stay active in the body?

The elimination half-life in humans is approximately 16–24 hours based on Phase I trials. This supports once-daily dosing in research protocols. Steady-state plasma concentrations are reached after 3–5 days of consistent administration.

---

This content is for informational and research purposes only. GW-501516 has not been approved by any regulatory authority for human use and was discontinued from clinical development due to cancer risk in animal studies. No long-term human safety data exists. Consult a qualified healthcare provider before considering any experimental compound for personal use.